Douglas E. Faries

9.3k total citations · 2 hit papers
154 papers, 7.0k citations indexed

About

Douglas E. Faries is a scholar working on Psychiatry and Mental health, Economics and Econometrics and Statistics and Probability. According to data from OpenAlex, Douglas E. Faries has authored 154 papers receiving a total of 7.0k indexed citations (citations by other indexed papers that have themselves been cited), including 79 papers in Psychiatry and Mental health, 44 papers in Economics and Econometrics and 33 papers in Statistics and Probability. Recurrent topics in Douglas E. Faries's work include Health Systems, Economic Evaluations, Quality of Life (43 papers), Schizophrenia research and treatment (39 papers) and Attention Deficit Hyperactivity Disorder (27 papers). Douglas E. Faries is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (43 papers), Schizophrenia research and treatment (39 papers) and Attention Deficit Hyperactivity Disorder (27 papers). Douglas E. Faries collaborates with scholars based in United States, United Kingdom and Canada. Douglas E. Faries's co-authors include Haya Ascher‐Svanum, Baojin Zhu, John H. Heiligenstein, Thomas Spencer, Joseph A. Johnston, Tessa Kennedy‐Martin, Sarah L. Hulin-Curtis, Susan Robinson, Joachim Wernicke and Douglas K. Kelsey and has published in prestigious journals such as The Lancet, SHILAP Revista de lepidopterología and Journal of the American Statistical Association.

In The Last Decade

Douglas E. Faries

146 papers receiving 6.7k citations

Hit Papers

A literature review on the representa... 2001 2026 2009 2017 2015 2001 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results
    2015 586 citations Douglas E. Faries, Joseph A. Johnston et al. profile →
  2. Atomoxetine in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: A Randomized, Placebo-Controlled, Dose-Response Study
    2001 529 citations Douglas E. Faries et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Douglas E. Faries United States 42 4.4k 1.4k 1.1k 942 733 154 7.0k
Jason Karlawish United States 59 4.3k 1.0× 1.8k 1.3× 1.1k 1.0× 411 0.4× 1.8k 2.5× 342 11.5k
Kwan Hur United States 31 2.0k 0.5× 1.4k 1.0× 683 0.6× 534 0.6× 393 0.5× 73 6.7k
Leslie Citrome United States 58 8.9k 2.0× 2.9k 2.1× 925 0.8× 2.1k 2.2× 564 0.8× 435 13.3k
W. Wolfgang Fleischhacker Austria 64 7.2k 1.6× 2.1k 1.4× 1.6k 1.4× 1.2k 1.3× 449 0.6× 266 11.1k
T. Scott Stroup United States 63 13.6k 3.1× 3.5k 2.5× 1.1k 1.0× 1.8k 2.0× 1.4k 2.0× 185 18.8k
Werner Kissling Germany 55 9.8k 2.2× 3.4k 2.4× 820 0.7× 2.0k 2.1× 868 1.2× 205 14.1k
Clive E Adams United Kingdom 43 3.7k 0.8× 2.9k 2.0× 291 0.3× 671 0.7× 578 0.8× 210 7.8k
Kristian Wahlbeck Finland 57 4.2k 1.0× 3.0k 2.1× 364 0.3× 714 0.8× 466 0.6× 202 10.3k
Sati Mazumdar United States 46 2.7k 0.6× 1.9k 1.3× 1.3k 1.2× 1.9k 2.1× 337 0.5× 155 8.4k
José Luis Vázquez‐Barquero Spain 49 4.0k 0.9× 2.2k 1.5× 1.0k 0.9× 545 0.6× 175 0.2× 148 7.4k

Countries citing papers authored by Douglas E. Faries

Since Specialization
Citations

This map shows the geographic impact of Douglas E. Faries's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas E. Faries with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas E. Faries more than expected).

Fields of papers citing papers by Douglas E. Faries

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas E. Faries. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas E. Faries. The network helps show where Douglas E. Faries may publish in the future.

Co-authorship network of co-authors of Douglas E. Faries

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas E. Faries. A scholar is included among the top collaborators of Douglas E. Faries based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas E. Faries. Douglas E. Faries is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tan, Xiaoqing, Shu Yang, Wenyu Ye, et al.. (2025). Double machine learning methods for estimating average treatment effects: a comparative study. Journal of Biopharmaceutical Statistics. 35(6). 1176–1195.
2.
3.
Yang, Shu, et al.. (2024). Improving randomized controlled trial analysis via data-adaptive borrowing. Biometrika. 112(2). asae069–asae069. 1 indexed citations
4.
Yang, Shu, et al.. (2024). Propensity score matching for estimating a marginal hazard ratio. Statistics in Medicine. 43(14). 2783–2810.
5.
Kaizar, Eloise, Chen‐Yen Lin, Douglas E. Faries, & Joseph A. Johnston. (2023). Reweighting estimators to extend the external validity of clinical trials: methodological considerations. Journal of Biopharmaceutical Statistics. 33(5). 515–543. 3 indexed citations
6.
Shan, Mingyang, et al.. (2022). A Simulation-Based Evaluation of Statistical Methods for Hybrid Real-World Control Arms in Clinical Trials. Statistics in Biosciences. 14(2). 259–284. 4 indexed citations
7.
Choong, Casey, Mark Belger, Alisa E. Koch, et al.. (2022). Comparative Effectiveness of Dexamethasone in Hospitalized COVID-19 Patients in the United States. Advances in Therapy. 39(10). 4723–4741.
8.
9.
Lipton, Richard B., Robert A. Nicholson, Michael L. Reed, et al.. (2022). Diagnosis, consultation, treatment, and impact of migraine in the US: Results of the OVERCOME (US) study. Headache The Journal of Head and Face Pain. 62(2). 122–140. 76 indexed citations
10.
Yang, Shu, et al.. (2021). Practical recommendations on double score matching for estimating causal effects. Statistics in Medicine. 41(8). 1421–1445. 8 indexed citations
11.
Nowell, W. Benjamin, Jeffrey R. Curtis, David Curtis, et al.. (2019). Digital Tracking of Rheumatoid Arthritis Longitudinally (DIGITAL) Using Biosensor and Patient-Reported Outcome Data: Protocol for a Real-World Study. JMIR Research Protocols. 8(9). e14665–e14665. 15 indexed citations
12.
Hunter, Craig, Noam Y. Kirson, Urvi Desai, et al.. (2015). Medical costs of Alzheimer's disease misdiagnosis among US Medicare beneficiaries. Alzheimer s & Dementia. 11(8). 887–895. 48 indexed citations
13.
Cui, Zhanglin Lin, Douglas E. Faries, Wei Shen, Stephen L. Able, & Diego Novick. (2013). Longitudinal analysis of healthcare costs: a case study of patients with major depressive disorder treated with duloxetine. Journal of Medical Economics. 16(5). 623–632. 1 indexed citations
14.
Robinson, R.L., Kurt Kroenke, David A. Williams, et al.. (2013). Longitudinal Observation of Treatment Patterns and Outcomes for Patients with Fibromyalgia: 12-Month Findings from the REFLECTIONS Study. Pain Medicine. 14(9). 1400–1415. 35 indexed citations
15.
Faries, Douglas E., Yi Chen, Ilya Lipkovich, et al.. (2013). Local control for identifying subgroups of interest in observational research: persistence of treatment for major depressive disorder. International Journal of Methods in Psychiatric Research. 22(3). 185–194. 13 indexed citations
16.
17.
Houston, John P., Kurt Kroenke, Douglas E. Faries, et al.. (2011). A Provisional Screening Instrument for Four Common Mental Disorders in Adult Primary Care Patients. Psychosomatics. 52(1). 48–55. 23 indexed citations
18.
Saylor, Keith E., et al.. (2007). The Life Participation Scale for Attention-Deficit/Hyperactivity Disorder–Child Version: Psychometric Properties of an Adaptive Change Instrument. Journal of Child and Adolescent Psychopharmacology. 17(6). 831–842. 16 indexed citations
19.
Ascher‐Svanum, Haya, et al.. (2006). Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatry. 6(1). 8–8. 96 indexed citations
20.
Faries, Douglas E., John H. Heiligenstein, G.D. Tollefson, & William Z. Potter. (2001). The Double-Blind Variable Placebo Lead-in Period: Results From Two Antidepressant Clinical Trials. Journal of Clinical Psychopharmacology. 21(6). 561–568. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jason Karlawish Breakdown of academic impact, for papers by Kwan Hur Breakdown of academic impact, for papers by Leslie Citrome Breakdown of academic impact, for papers by W. Wolfgang Fleischhacker Breakdown of academic impact, for papers by T. Scott Stroup Breakdown of academic impact, for papers by Werner Kissling Breakdown of academic impact, for papers by Clive E Adams Breakdown of academic impact, for papers by Kristian Wahlbeck Breakdown of academic impact, for papers by Sati Mazumdar Breakdown of academic impact, for papers by José Luis Vázquez‐Barquero
Rankless by CCL
2026